42
Participants
Start Date
May 30, 2017
Primary Completion Date
January 15, 2021
Study Completion Date
January 15, 2021
HYQVIA
Immune Globulin Infusion 10% (Human) with Recombinant Human Hyaluronidase (IGI, 10% with rHuPH20)
KIOVIG
100 mg/ml solution for Immune Globulin Intravenous Infusion
Cuvitru
200 mg/ml solution for Immune Globulin Subcutaneous Injection
Rigshospitalet, Copenhagen
FN v Motole Interni klinika, Prague
Groupe Hospitalier Pellegrin - Hôpital des Enfants, Bordeaux
CHU Angers - Hôpital Hôtel Dieu, Angers
Fakultni nemocnice Brno Odd. Detska klinika, Brno
Hospices Civils de Lyon - Hôpitaux Est - IHOP, Lyon
1.Detská klinika, Bratislava
Fakultní nemocnice Hradec Králové, Nový Hradec Králové
Agia Sophia Children's Hospital, Athens
General Hospital of Thessaloniki Ippokrateio, Thessaloniki
General Hospital of Thessaloniki Papageorgiou, Thessaloniki
United St. Istvan and St. Laszlo Hospital, Budapest
Univerzitna Nemocnica Klinika detí a dorastu, Martin
Queen Silvia Children's Hospital, Gothenburg
Dept. of Pediatric Oncology/Hematology/Immunology-Skånes Universitetssjukhus, Lund
Bristol Royal Hospital for Children, Bristol
Leeds Children's Hospital, Leeds
Royal Victoria Hospital, Belfast
University Hospital of Wales Heath Park Clinical Research Facility, Cardiff
The Great North Children's Hospital Royal Victoria Infirmary, Newcastle upon Tyne
Baxalta Innovations GmbH, now part of Shire
INDUSTRY
Baxalta now part of Shire
INDUSTRY